Page last updated: 2024-08-21

vancomycin and iclaprim

vancomycin has been researched along with iclaprim in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's9 (64.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hawser, S; Islam, K; Schneider, P1
Fritsche, TR; Jones, RN; Sader, HS1
Entenza, JM; Giddey, M; Haldimann, A; Hawser, S; Lociuro, S; Moreillon, P1
Hawser, S; Islam, K; Laue, H; Lociuro, S; Seguin, A; Valensise, T1
Barrow, EW; Barrow, WW; Berlin, KD; Bourne, CR; Bourne, PC; Bunce, RA1
Brandt, R; Hadvary, P; Hawser, S; Islam, K; Krievins, D1
Corey, GR; Dryden, M; File, TM; Hadvary, P; Huang, DB; Shorr, AF; Torres, A; Wilcox, MH1
Amin, F; Corey, GR; Dryden, M; File, TM; Heller, B; Holland, TL; Huang, DB; McLeroth, P; O'Riordan, W; Overcash, JS; Shukla, R; Torres, A; Wilcox, MH1
Borghei, A; Corey, GR; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; McLeroth, P; McManus, A; O'Riordan, W; Oguri, T; Shin, E; Shukla, R; Torres, A; Wilcox, MH1
Balser, B; Corey, GR; Desplats, E; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; O'Riordan, W; Torres, A; Wilcox, MH1
Huang, D; Lodise, T; Patel, N1
Bryant, AE; Gomi, S; Huang, DB; Katahira, E; Stevens, DL1
Balser, B; Corey, GR; Huang, DB; Noviello, S; Scaramucci, A1
Charrier, C; Hawser, S; Huang, DB; Le Bras, C; Noviello, S1

Trials

7 trial(s) available for vancomycin and iclaprim

ArticleYear
Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:7

    Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Pyrimidines; Skin Diseases, Infectious; Staphylococcus aureus; Vancomycin; Young Adult

2009
A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens.
    Clinical therapeutics, 2017, Volume: 39, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cross Infection; Double-Blind Method; Female; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pneumonia; Pyrimidines; Treatment Outcome; Vancomycin

2017
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Path
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 04-03, Volume: 66, Issue:8

    Topics: Administration, Intravenous; Adult; Anti-Bacterial Agents; Double-Blind Method; Female; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Male; Middle Aged; Pyrimidines; Skin; Skin Diseases, Bacterial; Treatment Outcome; Vancomycin

2018
A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Path
    Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:5

    Topics: Administration, Intravenous; Adult; Aged; Female; Gram-Positive Bacteria; Humans; Male; Middle Aged; Pyrimidines; Skin Diseases, Bacterial; Vancomycin

2018
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    International journal of antimicrobial agents, 2018, Volume: 52, Issue:2

    Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin

2018
A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies.
    Clinical therapeutics, 2019, Volume: 41, Issue:6

    Topics: Administration, Intravenous; Anti-Bacterial Agents; Double-Blind Method; Humans; Pyrimidines; Skin Diseases, Bacterial; Substance Abuse, Intravenous; Treatment Outcome; Vancomycin

2019
The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
    Journal of medical microbiology, 2019, Volume: 68, Issue:6

    Topics: Acute Disease; Anti-Bacterial Agents; Double-Blind Method; Humans; Incidence; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Skin; Staphylococcal Skin Infections; Staphylococcus aureus; Vancomycin

2019

Other Studies

7 other study(ies) available for vancomycin and iclaprim

ArticleYear
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
    Bioorganic & medicinal chemistry letters, 2003, Dec-01, Volume: 13, Issue:23

    Topics: Animals; Drug Resistance, Bacterial; Folic Acid Antagonists; Lung; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Pyrimidines; Sepsis; Staphylococcus aureus; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase; Trimethoprim Resistance; Vancomycin

2003
Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:5

    Topics: Anti-Bacterial Agents; Enterococcus faecalis; Europe; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Hospitalization; Humans; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrimidines; Staphylococcus aureus; Streptococcus; United States

2009
Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mutation; Pyrimidines; Rats; Thymidine Kinase; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin

2009
In vitro bactericidal activity of iclaprim in human plasma.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:10

    Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Plasma; Pyrimidines; Staphylococcus aureus

2009
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum dihydrofolate reductase inhibitor RAB1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9

    Topics: Anti-Bacterial Agents; Enzyme Inhibitors; Inhibitory Concentration 50; Microbial Sensitivity Tests; Protein Structure, Secondary; Protein Structure, Tertiary; Staphylococcus aureus; Tetrahydrofolate Dehydrogenase

2010
Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
    Clinical drug investigation, 2018, Volume: 38, Issue:10

    Topics: Acute Kidney Injury; Anti-Bacterial Agents; Cost Savings; Folic Acid Antagonists; Hospitalization; Humans; Pyrimidines; Skin Diseases, Infectious; Vancomycin

2018
The effects of iclaprim on exotoxin production in methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Journal of medical microbiology, 2019, Volume: 68, Issue:3

    Topics: Anti-Bacterial Agents; Bacterial Toxins; Biological Assay; Exotoxins; Folic Acid Antagonists; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcus aureus; Trimethoprim; Vancomycin; Virulence Factors

2019